G. Rondón

A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation.

J. Vose, A. Nademanee, J. Fay, 1998, Blood.

Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs.

R. Champlin, J. Hester, P. Bojko, 1996, Transfusion science.

Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, R. Champlin, 1997, Seminars in oncology.

Principles of bone marrow processing and progenitor cell/mononuclear cell concentrate collection in a continuous flow blood cell separation system.

A. Deisseroth, R. Champlin, Y. Huh, 1995, Journal of hematotherapy.

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.

A. Gee, I. Braunschweig, J. Gajewski, 2000, Cytotherapy.

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

B. Andersson, M. Qazilbash, R. Champlin, 2009 .

Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS

B. Andersson, M. Qazilbash, R. Champlin, 2008 .